Search
Olaratumab
go.drugbank.com/drugs/DB06043ApprovedInvestigationalOlaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity … It is composed of two heavy chain molecule fragments and 2 light chain fragments.
Categories: Platelet-derived Growth Factor Receptor alpha AntagonistTC-2216
go.drugbank.com/drugs/DB06044InvestigationalTC-2216 is an investigational novel small molecule that is being developed as an oral treatment for depression and anxiety disorders. TC-2216 showed greater potency than and anti-depressant effects comparable to selective serotonin reupt...
Synonyms: 1,7-DIAZASPIRO(4.4)NONANE, 7-(3-PYRIDINYL)-, HYDROCHLORIDE (1:3)Lumateperone
go.drugbank.com/drugs/DB06077ApprovedInvestigationalSchizophrenia is a complex mental illness and impacts approximately 1% of the population. … [A189093] It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology
Categories: Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor AntagonistsCaplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker.
Products: CABLIVI®, Cablivi 10 mg/1 mL Enjeksiyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 1 ADETICA-105665
go.drugbank.com/drugs/DB06089InvestigationalIt is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. … ICA-105665 is a novel small molecule compound for the treatment of epilepsy.
ISIS 325568
go.drugbank.com/drugs/DB06099InvestigationalISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR). … It was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping control type 2 diabetes.
VX-148
go.drugbank.com/drugs/DB06103ExperimentalThe IMPDH enzyme plays a key role in regulating immune response and proliferation of specific cell types, including lymphocytes. VX-148 is a developed for the treatment of autoimmune diseases. … VX-148 is a second-generation, orally administered inhibitor of inosine monophosphate dehydrogenase (IMPDH).
MDX-214
go.drugbank.com/drugs/DB06110ExperimentalIt is developed for the treatment of EGF-R overexpressing cancers. … MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector
PGX-100
go.drugbank.com/drugs/DB06114InvestigationalIt is a nearly nonanticoagulant heparin derivative that retains its anti-inflammatory activity.
Dimethylcurcumin
go.drugbank.com/drugs/DB06133InvestigationalDimethylcurcumin is a synthetic chemical compound that is loosely based on a compound found in curcumin. It is a novel anti-androgen that enhances androgen receptor degradation.